IDEXX LABORATORIES INC /DE Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Idexx Laboratories Inc /De quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Idexx Laboratories Inc /De Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $15.7M, a 1.95% increase year-over-year.
  • Idexx Laboratories Inc /De Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $60.5M, a 8.94% increase year-over-year.
  • Idexx Laboratories Inc /De annual Share-based Payment Arrangement, Expense for 2023 was $59.7M, a 20% increase from 2022.
  • Idexx Laboratories Inc /De annual Share-based Payment Arrangement, Expense for 2022 was $49.8M, a 31.8% increase from 2021.
  • Idexx Laboratories Inc /De annual Share-based Payment Arrangement, Expense for 2021 was $37.8M, a 22% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $59.7M +$9.97M +20% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 $49.8M +$12M +31.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 $37.8M +$6.8M +22% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 $31M -$8.33M -21.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-16
2019 $39.3M +$14.1M +56.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-16
2018 $25.2M +$1.64M +6.97% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 $23.5M +$3.63M +18.2% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 $19.9M +$7K +0.04% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-15
2015 $19.9M +$1.79M +9.86% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-16
2014 $18.1M Jan 1, 2014 Dec 31, 2014 10-K 2017-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.